Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Targets Chronic Urticaria As Ligelizumab Enters Late-Stage Trials

Executive Summary

Two Phase III studies, PEARL 1 and PEARL 2, will compare Novartis's candidate anti-IgE antibody with the previous generation anti-IgE MAb, Xolair, for the treatment of chronic spontaneous urticaria.

You may also be interested in...



Novartis’s Ligelizumab Founders In Phase III Despite Positive Predictions

Novartis’s ligelizumab failed to show superiority over standard of care Xolair, subverting hopeful analyst expectations and changing the firm’s focus in chronic spontaneous urticaria to a BTK inhibitor asset.

Keeping Track: US FDA Approves Esperoct, Tightens Chantix Label, Starts Review Of Alder’s CGRP Candidate

The latest drug development news and highlights from our US FDA Performance Tracker.

ICER On Asthma Biologics: 50%-79% Price Discounts Needed To Meet Value Assessment Metrics

The independent value assessment organization’s draft assessment found that the prices for all five marketed biologics for severe asthma – Xolair, Nucala, Cinqair, Fasenra and Dupixent – far exceed standard cost-effectiveness thresholds.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC124278

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel